TGFBR1 and cardiac hypertrophy: Additionally, TGFBR1 gene silencing significantly reduced the HFD + L-NAME–induced increases in diastolic and systolic blood pressure and NT-proBNP, a marker of HF, and improved exercise intolerance, cardiac hypertrophy, and pulmonary edema (Fig 2N–R).